BI 3923948
/ Boehringer Ingelheim
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 23, 2026
1538-0001: A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)
(clinicaltrialsregister.eu)
- P1 | N=35 | Not yet recruiting | Sponsor: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1